We would like to thank Larroumet et al. (1) for their interest in our article (2) and for sharing their institution’s significant experience (3). Certainly, admission to a specialized ward can durably improve the HbA1c control in patients with uncontrolled type 2 diabetes (T2D). Investigating this concept was not part of our initial intention and research focus; rather, our focus was to develop a prediction model regarding the probability of HbA1c goal attainment in patients with uncontrolled T2D.
As the authors acknowledge in their letter, the organization of health systems in many countries may preclude using such an intervention. In the absence of life-threatening symptoms, hospitalizations for uncontrolled T2D in the U.S. are uncommon. Hospitalizations, which may have occurred in our subjects, would not have been in a specialized ward designed specifically for the management of uncontrolled T2D, so we are unable to provide such data in our response. This may be an interesting area for us to explore with future research.
Article Information
Duality of Interest. This project and the assistance in preparing and coordinating the publication of the original manuscript were funded by Novo Nordisk Inc. K.M.P. reports receiving research funding from Bayer, Novo Nordisk Inc., and Merck; receiving consulting fees from AstraZeneca, Bayer, Corcept Therapeutics, Eli Lilly, Novo Nordisk Inc., and Merck; and participating in the speakers bureaus of AstraZeneca, Novo Nordisk Inc., and Merck within the past 12 months. A.D.M.-H. has received research support from Bayer, Merck, Novo Nordisk Inc., and the Agency for Healthcare Research and Quality (K08 HS024128) within the past 12 months. B.B. reports receiving consulting fees and research support from Novo Nordisk Inc. within the past 12 months. M.W.K. reports receiving research funding from Bayer, Merck, and Novo Nordisk Inc. within the past 12 months. No other potential conflicts of interest relevant to this article were reported.
